QT Vascular in potential sale of coronary products
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
MEDICAL technology firm QT Vascular is potentially selling its coronary products to a multinational firm.
In an announcement on Monday morning, it said that the term sheet both have entered into is non-legally binding and non-definitive, and it will continue to engage the buyer with the intention to complete the deal.
The Catalist-listed firm aims to continue generating value for shareholders from its mature products while further developing its drug-coated products and expanding its portfolio with new technologies, it added.
QT Vascular had also announced a potential transaction linked to certain coronary assets in October last year, which led to a surge in its share price.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
